Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Patients with Advanced Urinary Tract Cancer

Objectives: This randomized placebo-controlled phase III trial asks whether adding bevacizumab (Avastin) to a gemcitabine (Gemzar) and cisplatin regimen can improve overall survival.

Key entry or exclusion criteria: Patients cannot be a candidate for potentially curative surgery or radiotherapy.

Locations: 497 sites.

Goal: 500 patients.

Study sponsor: Cancer and Leukemia Group B in collaboration with the National Cancer Institute.

Link for more information: clinicaltrials.gov/ct2/show/NCT00942331

NIH clinical trials identifier: NCT00942331

Objectives: This randomized placebo-controlled phase III trial asks whether adding bevacizumab (Avastin) to a gemcitabine (Gemzar) and cisplatin regimen can improve overall survival.

Key entry or exclusion criteria: Patients cannot be a candidate for potentially curative surgery or radiotherapy.

Locations: 497 sites.

Goal: 500 patients.

Study sponsor: Cancer and Leukemia Group B in collaboration with the National Cancer Institute.

Link for more information: clinicaltrials.gov/ct2/show/NCT00942331

NIH clinical trials identifier: NCT00942331

Objectives: This randomized placebo-controlled phase III trial asks whether adding bevacizumab (Avastin) to a gemcitabine (Gemzar) and cisplatin regimen can improve overall survival.

Key entry or exclusion criteria: Patients cannot be a candidate for potentially curative surgery or radiotherapy.

Locations: 497 sites.

Goal: 500 patients.

Study sponsor: Cancer and Leukemia Group B in collaboration with the National Cancer Institute.

Link for more information: clinicaltrials.gov/ct2/show/NCT00942331

NIH clinical trials identifier: NCT00942331